EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study

Wen Lyu, Rui Xu iD, Lin Chen, Wenbin Lei, Changhui Chen iD, Jiaqi Liao, Xingyu Lin, Renqiang Ma iD, Weiping Wen iD, Hang Li

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.05.2026. Verfasst von Wen Lyu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Neoplasms, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics targeting Type 2 immune responses, such as omalizumab (anti‐IgE), dupilumab (anti‐interleukin‐4 receptor alpha, anti‐IL‐4Rα), benralizumab (anti‐IL‐5R), reslizumab, and mepolizumab (anti‐IL‐5), are increasingly used clinically. Emerging evidence suggests potential associations between biologics and neoplastic events.

Methods

We analyzed the FDA Adverse Event Reporting System (FAERS) database reports for omalizumab, dupilumab, benralizumab, reslizumab, and mepolizumab from their respective market dates to Q1 2025. To enhance comparability, this analysis was restricted to the asthma indication for all 5 biologics. Neoplasm‐related adverse events (AEs) were assessed using disproportionality analysis and multivariable logistic regression analysis.

Results

A total of 2316 neoplasm‐related AE reports were identified (974 omalizumab, 322 dupilumab, 369 benralizumab, and 651 mepolizumab). Increased reporting may reflect higher biologic use, reporting biases, or system inherent biases. The most common neoplasms reported for omalizumab, dupilumab, benralizumab, and mepolizumab were breast cancer (13.23%, 15.25%, 14.9%, 9.21%), malignant lung neoplasm (5.86%, 5.28%, 5.56%, 6.74%), and prostate cancer (3.29%, 5.87%, 3.54%, 5.06%). All biologics had significant disproportionality signals. Despite low reporting frequency, several neoplasms demonstrated strong signals with biologics of interest. Notably, dupilumab exhibited a strong and specific signal for cutaneous T‐cell lymphoma (ROR = 6.1, 95% CI: 1.76–21.06). Similar patterns were likewise observed in the multivariable logistic regression analysis.

Conclusion

This pharmacovigilance study detected neoplasm‐related disproportionality signals for anti‐Type 2 biologics. Causality cannot be established due to spontaneous reporting limitations. Clinicians should be aware of these disproportionality signals and maintain vigilance during long‐term clinical management of patients receiving anti‐Type 2 biologic therapy to ensure optimal patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBiological ProductsHumansPharmacovigilanceAdverse Drug Reaction Reporting SystemsAntibodies, Monoclonal, HumanizedDatabases, FactualFemaleUnited StatesMaleOmalizumab

Stichwörter der Autor:innen

adverse drug reactionsadverse eventsbiologicsdisproportionality analysismonoclonal antibodiesneoplasm

Substanzen

Antibodies, Monoclonal, HumanizedBiological ProductsOmalizumabbenralizumabdupilumab

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Allergy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Otorhinolaryngology Institute of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guangzhou Key Laboratory of Otorhinolaryngology, Guangzhou, Guangdong, China.

ORCID-Profile: Rui Xu, Changhui Chen, Renqiang Ma, Weiping Wen

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangzhou Science and Technology Plan Project
  • Kelin New Star Program of the First Affiliated Hospital of Sun Yat-sen University

Zitieren

APA

Lyu, W., Xu, R., Chen, L., Lei, W., Chen, C., Liao, J., Lin, X., Ma, R., Wen, W., & Li, H. (2026). Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71979

Vancouver

Lyu W, Xu R, Chen L, Lei W, Chen C, Liao J, et al. Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71979

BibTeX
@article{Lyu2026,
  author = {Lyu, Wen and Xu, Rui and Chen, Lin and Lei, Wenbin and Chen, Changhui and Liao, Jiaqi and Lin, Xingyu and Ma, Renqiang and Wen, Weiping and Li, Hang},
  title = {Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71979}
}
Kostenlos starten →